Drug Shortages Domestic Manufacturing Tariffs
2025 · 3rd Quarter (July 1 - Sep 30)
FRESENIUS KABI USA LLC
Filed by FRESENIUS KABI USA LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Amendment
- Posted
- Nov 25, 2025
- Income
- Not reported
- Expenses
- $340,000.00
- Registrant
- FRESENIUS KABI USA LLC
- Client
- FRESENIUS KABI USA LLC
- Filing UUID
- 51899457-afae-4485-8e5f-b7383137aafa
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Drug Shortages and Medicaid ERISA Fiduciary Duty IRA Reform
S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 1041: Affordable Prescriptions for Patients Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 43: Skinny Labels, Big Savings Act S. 1097/H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 HR 4317: PBM Reform Act of 2025 HR 2214: DRUG Act S. 1553/H.R. 3160: PREVAIL Act S. 2305: Biosimilar Red Tape Elimination Act S. 2658: Medication Affordability and Patient Integrity Act ERISA Fiduciary Duty PTAB Discretionary Denials IRA Reform Human Factor Studies Interchangeability Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing
Literal federal measure citations: S. 1954, H.R. 5526, S. 1414, S. 2276, H.R. 3269, S. 1041, S. 1096, S. 43, S. 1097, H.R. 4570, HR 4317, HR 2214, S. 1553, H.R. 3160, S. 2305, S. 2658
Domestic Manufacturing
Domestic Manufacturing Tariffs
PTAB Discretionary Denials
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.